VHEP方案治疗多发性骨髓瘤的初步报告

目的：观察含羟基喜树碱和鬼臼乙叉甙的VHEP方案治疗多发性骨髓瘤（MM）的疗效、毒副反应。方法：16例患者经临床及各项实验室检查确诊为MN，采用VHEP方案化疗1～3疗程，观察其疗效及不良反应。结果：VHEP方案化疗后部分缓解（PR）率是43．75％，达到PR的中位时间为72d。M蛋白下降50％以上为43．75％，瘤细胞下降80％的患者占43．75％，治疗前后血钙、血肌酐、谷丙转氨酶无明显变化，sLDH及血清β2-微球蛋白治疗后较治疗前明显减低。结论：VHEP方案提高了MM患者的部分缓解率，发挥明显疗效的时间较长，对骨髓抑制作用较轻，无明显毒性，是一种安全有效的治疗方案。

Treatment of multiple myeloma with VHEP regimen: a preliminary report of 16 cases

Objective： To survey the therapeutic effect and side effect of VHEP regimen including hydroxycamptothecin （HCPT）and etoposide （VP- 16） in the treatment of multiple myeloma （MM）. Methods： Sixteen MM patients diagnosed by clinical and laboratory data were treated by VHEP regimen （ 1 to 3 courses）, and the therapeutic effect and side effect were observed. Results：The rate of partial remission （PR） was 43.75% after treatment with VHEP regimen, the median time to achieve PR was 72 days. The M globulin level decreased to less than 50% of the pre - treatment level in 43.75% patients, and the number of myeloma cells in bone marrow was reduced to 20% of pre -treatment level in 43.75 % patients. There was no significant difference in serum calcium, creatinine and GPT before and after treatment, and the levels of sLDH and serum microglobin were significantly lower than those before treatment. Conclusion： The VHEP regimen may enhance the PR rate of MM patients, but it takes longer time to achieve PR, and shows mild bone marrow inhibition with no significant toxicity. The VHEP regimen is effective and safe for treatment of MM.